Clinical trials · Washington, D.C., DC
Crohn’s disease clinical trials in Washington, D.C.
We’re tracking 26 recruiting crohn’s disease studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06065228Recruiting
Tracking treatment progress in children with IBD
This study looks at a new way to measure how well treatment is working in children with inflammatory bowel disease (IBD). It uses a special eye test called pupillometry, which is painless and non-invasive, to see if it can help doctors adjust treatment earlier.
Washington D.C., District of ColumbiaAges 6–21 - NCT02791854Enrolling by invitation
Improving Care for Adults With Crohn’s or Ulcerative Colitis
This trial looks at ways to improve care for adults living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. You may be invited if your clinic is part of an inflammatory bowel disease care network called IBD Qorus.
Washington D.C., District of ColumbiaAges 18–99 - NCT05230173Recruiting
Treat to endoscopic remission in inflammatory bowel disease
This study tests whether switching to a different treatment for inflammatory bowel disease (IBD) can achieve healing of the gut lining. It is for people whose symptoms are under control but who still have significant inflammation in their bowel.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Washington D.C., District of ColumbiaAges 16–80 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07619547Recruiting
Bowel disease immune system study
This study is looking at how the immune system works in people with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. By comparing blood or tissue samples from people with and without IBD, researchers hope to find better ways to treat the disease in the future.
Bethesda, MarylandAges 18–85 - NCT03167437RecruitingPhase 1/Phase 2
Vorinostat for uncontrolled Crohn’s or ulcerative colitis
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Bethesda, MarylandAges 18–65 - NCT00001184Recruiting
Studying the immune system in Crohn's and colitis
This study collects blood and tissue samples to better understand how the immune system behaves in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It aims to advance research rather than test a specific new treatment, and it also enrolls healthy volunteers for comparison.
Bethesda, MarylandAges 1 day–75 years - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Chevy Chase, MarylandAges 16–80 - NCT06750731Recruiting
IV vs. shot vedolizumab for IBD with remote check-ins
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Chevy Chase, MarylandAges 18 years+ - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
Chevy Chase, MarylandAges 18–80 - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chevy Chase, MarylandAges 18 years+ - NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Chevy Chase, MarylandAges 18–75 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Chevy Chase, MarylandAges 18–70 - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Fairfax, VirginiaAges 2–19 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Laurel, MarylandAges 16–80 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Lansdowne Town Center, VirginiaAges 16–80 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Lansdowne Town Center, VirginiaAges 18–75 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Glen Burnie, MarylandAges 18–75 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Glen Burnie, MarylandAges 18 years+ - NCT06764615RecruitingPhase 2
Long-term study of TAK-279 for ulcerative colitis and Crohn's disease
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
Glen Burnie, MarylandAges 18–75 - NCT05781152RecruitingPhase 4
Testing how new Crohn’s imaging and scopes predict outcomes
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
Baltimore, MarylandAges 6–17 - NCT06560021Enrolling by invitation
Random biopsies in inflammatory bowel disease surveillance
This trial looks at whether taking random biopsies during a routine colonoscopy is helpful for people with inflammatory bowel disease (IBD) who are at risk for colon cancer. It aims to understand if random biopsies can detect early signs of cancer or pre-cancer.
Baltimore, MarylandAges 18 years+ - NCT07237516Recruiting
Study of Zymfentra for people with Crohn's or colitis
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
Baltimore, MarylandAges 18 years+
Hear when a new Crohn’s disease trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Crohn’s disease trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting crohn’s disease studies listed above.
- Woodholme Gastroenterology Associates · 5 studies
- National Institutes of Health Clinical Center · 4 studies
- Capital Digestive Care · 3 studies
- Mercy Medical Center · 3 studies
- Chevy Chase Clinical Research · 2 studies
- MedStar Georgetown University Hospital · 2 studies
- Children's National Health System
- Emeritas Research Group
What taking part in a crohn’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting crohn’s disease studies in District of Columbia.
Common questions
- Are there crohn’s disease clinical trials near Washington, D.C.?
- Yes. We're currently tracking 26 recruiting crohn’s disease studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a crohn’s disease study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a crohn’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New crohn’s disease studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.